Molecular Oncology
Volume 4, Issue 1 , Pages 38-51 , February 2010

Topoisomerase IIα-dependent induction of a persistent DNA damage response in response to transient etoposide exposure

  • Sébastien Soubeyrand

      Affiliations

    • The Ottawa Health Research Institute, University of Ottawa, 451 Smyth Road, Ottawa, ON K1H 8M5, Canada
    • ,
  • Louise Pope

      Affiliations

    • The Ottawa Health Research Institute, University of Ottawa, 451 Smyth Road, Ottawa, ON K1H 8M5, Canada
    • ,
  • Robert J.G. Haché

      Affiliations

    • The Ottawa Health Research Institute, University of Ottawa, 451 Smyth Road, Ottawa, ON K1H 8M5, Canada
    • Department of Medicine and Biochemistry, Microbiology and Immunology, University of Ottawa, 451 Smyth Road, Ottawa, ON K1H 8M5, Canada
    • Corresponding Author InformationCorresponding author.

Received 17 August 2009 ,Revised 29 September 2009 ,Accepted 30 September 2009.

References 

  1. Adachi N, Iiizumi S, So S, Koyama H. Genetic evidence for involvement of two distinct nonhomologous end-joining pathways in repair of topoisomerase II-mediated DNA damage. Biochem. Biophys. Res. Commun. 2004;318:856–861
  2. Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford JM, Buggy JJ. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc. Natl. Acad. Sci. USA. 2007;104:19482–19487
  3. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 2003;421:499–506
  4. Bandele OJ, Osheroff N. The efficacy of topoisomerase II-targeted anticancer agents reflects the persistence of drug-induced cleavage complexes in cells. Biochemistry. 2008;47:11900–11908
  5. Chabner B, et al. Chemotherapy of neoplastic diseases: antineoplastic agents. In:  Brunton L,  Lazo J,  Parker K editor. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2005;p. 1315–1404
  6. Chan DW, Chen BP, Prithivirajsingh S, Kurimasa A, Story MD, Qin J, et al. Autophosphorylation of the DNA-dependent protein kinase catalytic subunit is required for rejoining of DNA double-strand breaks. Genes Dev. 2002;16:2333–2338
  7. Chen BP, et al. Ataxia telangiectasia mutated (ATM) is essential for DNA-PKcs phosphorylations at the Thr-2609 cluster upon DNA double strand break. J. Biol. Chem. 2007;282:6582–6587
  8. Chowdhury D, Keogh MC, Ishii H, Peterson CL, Buratowski S, Lieberman J. gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair. Mol. Cell. 2005;20:801–809
  9. Christensen MO, et al. Dynamics of human DNA topoisomerases IIalpha and IIbeta in living cells. J. Cell Biol. 2002;157:31–44
  10. Cucinotta FA, Pluth JM, Anderson JA, Harper JV, O’Neill P. Biochemical kinetics model of DSB repair and induction of gamma-H2AX foci by non-homologous end joining. Radiat. Res. 2008;169:214–222
  11. D’Arpa P, Liu LF. Topoisomerase-targeting antitumor drugs. Biochim. Biophys. Acta. 1989;989:163–177
  12. Danks MK, Qiu J, Catapano CV, Schmidt CA, Beck WT, Fernandes DJ. Subcellular distribution of the alpha and beta topoisomerase II–DNA complexes stabilized by VM-26. Biochem. Pharmacol. 1994;48:1785–1795
  13. Ding Q, Reddy YV, Wang W, Woods T, Douglas P, Ramsden DA, et al. Autophosphorylation of the catalytic subunit of the DNA-dependent protein kinase is required for efficient end processing during DNA double-strand break repair. Mol. Cell. Biol. 2003;23:5836–5848
  14. Errington F, Willmore E, Leontiou C, Tilby MJ, Austin CA. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity. Cancer Chemother. Pharmacol. 2004;53:155–162
  15. Fan JR, Peng AL, Chen HC, Lo SC, Huang TH, Li TK. Cellular processing pathways contribute to the activation of etoposide-induced DNA damage responses. DNA Repair (Amst.). 2008;7:452–463
  16. Foray N, Priestley A, Alsbeih G, Badie C, Capulas EP, Arlett CF, et al. Hypersensitivity of ataxia telangiectasia fibroblasts to ionizing radiation is associated with a repair deficiency of DNA double-strand breaks. Int. J. Radiat. Biol. 1997;72:271–283
  17. Foster ER, Downs JA. Histone H2A phosphorylation in DNA double-strand break repair. FEBS J. 2005;272:3231–3240
  18. Fraser NW, Sehgal PB, Darnell JE. DRB-induced premature termination of late adenovirus transcription. Nature. 1978;272:590–593
  19. Goodarzi AA, Noon AT, Deckbar D, Ziv Y, Shiloh Y, Lobrich M, et al. ATM signaling facilitates repair of DNA double-strand breaks associated with heterochromatin. Mol. Cell. 2008;31:167–177
  20. Gorczyca W, Gong J, Ardelt B, Traganos F, Darzynkiewicz Z. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res. 1993;53:3186–3192
  21. Griffith TD, Tolmach LJ. Lethal response of HeLa cells to x-irradiation in the latter part of the generation cycle. Biophys. J. 1976;16:303–318
  22. Hennequin C, Giocanti N, Balosso J, Favaudon V. Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells. Cancer Res. 1994;54:1720–1728
  23. Houlbrook S, Addison CM, Davies SL, Carmichael J, Stratford IJ, Harris AL, et al. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br. J. Cancer. 1995;72:1454–1461
  24. Huang S, Deerinck TJ, Ellisman MH, Spector DL. The perinucleolar compartment and transcription. J. Cell Biol. 1998;143:35–47
  25. Jensen PB, Sehested M. DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide. Biochem. Pharmacol. 1997;54:755–759
  26. Ju BG, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, Glass CK, et al. A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science. 2006;312:1798–1802
  27. Kalwinsky DK, Look AT, Ducore J, Fridland A. Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemic lymphoblasts. Cancer Res. 1983;43:1592–1597
  28. Kantidze OL, Iarovaia OV, Razin SV. Assembly of nuclear matrix-bound protein complexes involved in non-homologous end joining is induced by inhibition of DNA topoisomerase II.J. Cell Physiol. 2006;207:660–667
  29. Kaufmann SH. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res. 1991;51:1129–1136
  30. Keogh MC, et al. A phosphatase complex that dephosphorylates gammaH2AX regulates DNA damage checkpoint recovery. Nature. 2006;439:497–501
  31. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 2003;63:7291–7300
  32. Kobayashi M, Adachi N, Aratani Y, Kikuchi A, Koyama H. Decreased topoisomerase IIalpha expression confers increased resistance to ICRF-193 as well as VP-16 in mouse embryonic stem cells. Cancer Lett. 2001;166:71–77
  33. Lieber MR. The mechanism of human nonhomologous DNA end joining. J. Biol. Chem. 2008;283:1–5
  34. Lieber MR, Ma Y, Pannicke U, Schwarz K. Mechanism and regulation of human non-homologous DNA end-joining. Nat. Rev. Mol. Cell. Biol. 2003;4:712–720
  35. Long BH, Musial ST, Brattain MG. Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Cancer Res. 1985;45:3106–3112
  36. Lou Z, Chen BP, Asaithamby A, Minter-Dykhouse K, Chen DJ, Chen J. MDC1 regulates DNA-PK autophosphorylation in response to DNA damage. J. Biol. Chem. 2004;279:46359–46362
  37. Mao Y, Desai SD, Ting CY, Hwang J, Liu LF. 26 S proteasome-mediated degradation of topoisomerase II cleavable complexes. J. Biol. Chem. 2001;276:40652–40658
  38. Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J. Cell. Biochem. 2004;92:223–237
  39. McClendon AK, Osheroff N. DNA topoisomerase II, genotoxicity, and cancer. Mutat. Res. 2007;623:83–97
  40. Montecucco A, Biamonti G. Cellular response to etoposide treatment. Cancer Lett. 2007;252:9–18
  41. Nitiss JL, Liu YX, Harbury P, Jannatipour M, Wasserman R, Wang JC. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res. 1992;52:4467–4472
  42. Relling MV, Yanishevski Y, Nemec J, Evans WE, Boyett JM, Behm FG, et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia. 1998;12:346–352
  43. Rogakou EP, Redon C, Boon C, Johnson K, Bonner WM. Rapid histone extraction for electrophoretic analysis. Biotechniques. 2000;28:38–4042, 46
  44. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol. Med. 2006;12:440–450
  45. Sedelnikova OA, Rogakou EP, Panyutin IG, Bonner WM. Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma-H2AX antibody. Radiat Res. 2002;158:486–492
  46. Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA double-strand break repair pathway choice. Cell Res. 2008;18:134–147
  47. Soubeyrand S, Torrance H, Giffin W, Gong W, Schild-Poulter C, Hache RJ. Activation and autoregulation of DNA-PK from structured single-stranded DNA and coding end hairpins. Proc. Natl. Acad. Sci. USA. 2001;98:9605–9610
  48. Soubeyrand S, Pope L, Pakuts B, Hache RJ. Threonines 2638/2647 in DNA-PK are essential for cellular resistance to ionizing radiation. Cancer Res. 2003;63:1198–1201
  49. Tanaka T, Halicka HD, Traganos F, Seiter K, Darzynkiewicz Z. Induction of ATM activation, histone H2AX phosphorylation and apoptosis by etoposide: relation to cell cycle phase. Cell Cycle. 2007;6:371–376
  50. Toyoda E, et al. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform. J. Biol. Chem. 2008;283:23711–23720
  51. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell. Biol. 2002;3:430–440
  52. Willmore E, Frank AJ, Padget K, Tilby MJ, Austin CA. Etoposide targets topoisomerase IIalpha and IIbeta in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique. Mol. Pharmacol. 1998;54:78–85
  53. Wist E, Prydz H. The effect of aphidicolin on DNA synthesis in isolated HeLa cell nuclei. Nucleic Acids Res. 1979;6:1583–1590
  54. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 1991;2:209–214
  55. Wright SE, Hines LH, White JC. Effects of the lipophilic anticancer drug teniposide (VM-26) on membrane transport. Chem. Biol. Interact. 1990;75:31–48
  56. Xiao H, Mao Y, Desai SD, Zhou N, Ting CY, Hwang J, et al. The topoisomerase IIbeta circular clamp arrests transcription and signals a 26S proteasome pathway. Proc. Natl. Acad. Sci. USA. 2003;100:3239–3244
  57. Zhang A, Lyu YL, Lin CP, Zhou N, Azarova AM, Wood LM, et al. A protease pathway for the repair of topoisomerase II–DNA covalent complexes. J. Biol. Chem. 2006;281:35997–36003

PII: S1574-7891(09)00112-4

doi: 10.1016/j.molonc.2009.09.003

Molecular Oncology
Volume 4, Issue 1 , Pages 38-51 , February 2010

Article Tools

* Image Usage & Resolution